Direct acting oral anticoagulants (DOACs) should not be used in patients with antiphospholipid syndrome (APS) – including patients with SLE – due to a high risk of thrombotic events, the Therapeutic Goods Administration (TGA) has advised. In a new safety advisory statement the regulator says apixaban (Eliquis), dabigatran etexilate (Pradaxa) and rivaroxaban (Xarelto) are not ...
Don’t use DOACS in APS, regulator advises
By Michael Woodhead
27 Aug 2019